Best Genomics Companies in London, United Kingdom
The 94 best Genomics companies in London, United Kingdom in 2026, ranked by funding and momentum. Funding, investors, founders, valuation, tech stack and live signals. Top: MiNA Therapeutics.
Our analysis of 50 Genomics companies
$7.8b in tracked funding; 84% of the stack-profiled cohort runs cloud-native; funding activity peaked in 2025.
Ranked: Best Genomics companies in London
| # | Company | Disclosed funding | Last round | Employees | Founder | Tech stack | Patents & IP focus | Recent signals |
|---|---|---|---|---|---|---|---|---|
| 1 | MiNA Therapeutics Provider of RNA activation therapeutics | $446M | 59 mo ago | 18 | Pal Saetrom Co-Founder | — | 183 patents saRNA gene activation therapeutics targeting HBG1/2, TMEM173, CEBPA for disease treatment | — |
| 2 | Genomics Provider of genomic risk assessment and prevention platform 64Patents top 19%Innovation top 24%Funding top 24%Talent top 28% All 9 signals ▾Patentstop 19% Innovationtop 24% Fundingtop 24% Talenttop 28% Moattop 32% Growthtop 45% Globaltop 46% Techtop 50% Marketbottom 40% Patents: 48 patents matched (strict assignee match) · 33 filings since 2022 vs 13 in 2017-21 Innovation: 48 patents (top 22% of patent-holders) · 33 filings since 2022 vs 13 in 2017-21 rank vs industry peers · Fliar Intelligence Index 64/100 | $161M | 29 mo ago | — | Rebecca H Founder & Principal | HubSpot CMS HubApple iCloud Mailcore-js+14 | 48 patents Software platforms for computational analysis of genomic sequencing data | — |
| 3 | ReViral Developer of antiviral compounds for RSV | $121M | 69 mo ago | 28 | Khattereh Ahmadi Co-Founder | — | 91 patents Antiviral benzodiazepine derivatives for treating respiratory syncytial virus infections | — |
| 4 | Nightstar Developer of gene therapies for retinal diseases | $100M | 107 mo ago | 15 | Dave Fellows CEO | — | — | — |
| 5 | DNA Electronics Developer of semiconductor‑based DNA‑sequencing systems for use in healthcare | $90M | 116 mo ago | 111 111 → 174 (+57%) | Christofer Toumazou Founder & Executive Chairman | WordPressMySQLPHP+19 | 123 patents Patents concentrated in chemistry & materials | — |
| 6 | AviadoBio Developer of gene therapies for neurodegenerative disorders | $80M | 54 mo ago | 38 38 → 70 (+84%) | Do Lee Co-Founder | WordPressApple iCloud MailMicrosoft 365+29 | 3 patents Antisense nucleic‑acid therapies targeting SOD1 for ALS and CNS drug delivery platforms. | 1 launch · 1 partnership |
| 7 | DnaNudge Provider of a lab-on‑chip wearable system for genetic diagnosis | $60M | 57 mo ago | 32 | Maria Karvela Co-Founder & CSO | — | 95 patents Point‑of‑care multiplex nucleic‑acid diagnostics with secure genetic data account management | — |
| 8 | Femtogenix Provider of DNA-interactive payload molecules for use in ADCs | $40M | 51 mo ago | 14 | Chris Keightley CEO | — | 43 patents Design of piperidinobenzodiazepine small‑molecule cytotoxic agents for cancer therapy | — |
| 9 | Sano Provider of clinical trial recruitment and genetic testing research services | $26M | 29 mo ago | 10 | Patrick Short Co-Founder & CEO | HubSpot CMS HubApple iCloud MailGoogle Workspace+16 | — | — |
| 10 | Tiziana Life Sciences Developer of small-molecule drugs for cancer and autoimmune diseases | $22M | 79 mo ago | 11 | — | DrupalPHPZURB Foundation+20 | 79 patents Patents concentrated in chemistry & materials | — |
| 11 | Treos Bio Developer of cancer vaccines and companion diagnostics | $22M | 62 mo ago | 12 12 → 16 (+33%) | — | — | 65 patents Personalized peptide-based cancer vaccines and immunogenic peptide discovery platforms | — |
| 12 | Suisse Life Science Direct to consumer genetic profiling and associated services | $20M | 95 mo ago | — | Omar Fogliadini Founder & CEO | — | — | — |
| 13 | Valirx Developer of novel technologies and products in oncology therapeutics and diagnostics | $14M | 84 mo ago | 7 | — | — | 16 patents Patents concentrated in chemistry & materials | 2 partnerships |
| 14 | Sixfold Bioscience Developer of oligonucleotide delivery systems | $10M | 54 mo ago | 16 | — | Webflowcore-jsjQuery+6 | 25 patents Nucleic‑acid nanoparticle platforms for therapeutic and diagnostic oligonucleotide delivery | — |
| 15 | iamYiam DNA-based health and fitness recommendations | $10M | 47 mo ago | 6 | Lorena Puica Founder & CEO | — | — | — |
| 16 | GenDaq Developer of technologies for regulation of gene expression | $10M | 314 mo ago | 11 | Yen Choo Founder | — | 48 patents Engineered DNA-binding proteins and peptide libraries for nucleic acid recognition applications. | — |
| 17 | Multus Provider of lab-grown meat alternatives | $9M | 41 mo ago | 8 | Kevin Pan Co-founder & CTO | — | — | — |
| 18 | MicrofluidX Provider of cell and gene based therapy | $9M | 32 mo ago | 10 | Antoine Espinet Co-Founder & CEO | — | 24 patents Microfluidic bioprocessing platforms for precise fluid handling and aseptic cell culture | — |
| 19 | Everything Genetic Provider of genetic testing for hereditary data of healthcare | $6M | 49 mo ago | 46 | — | — | — | — |
| 20 | Phytoform Labs Developer of genome editing and artificial intelligence tools for crop improvement | $6M | 54 mo ago | 8 | William Pelton Co-Founder & CEO | Webflowcore-jsjQuery+11 | 16 patents Plant genetic engineering, trait modification, and high-throughput screening for crop improvement | 1 job opening · 1 partnership |
| 21 | BioCorteX Developer of human-microbiome platform for drug development | $5M | 38 mo ago | 13 | Nik Sharma Co-Founder & CEO | — | — | 1 award |
| 22 | Desktop Genetics Provider of genome editing technologies to design and manage CRISPR experiments | $5M | 104 mo ago | 4 | — | — | — | — |
| 23 | Apta Biosciences Developer of a synthetic biology technology platform for diagnostics and therapeutics | $5M | 126 mo ago | 11 | William Addison Co-Founder & Director | — | 12 patents Patents concentrated in chemistry & materials | — |
| 24 | Inoviv Provider of biomarker tests for precision treatments | $3M | 28 mo ago | 6 | Michael Dove Co-Founder & CEO | WordPressMySQLPHP+30 | — | — |
| 25 | ConcR Provider of a platform predicting therapeutic response and outcome for cancer | $3M | 33 mo ago | 6 | Matt Foster CEO | Craft CMSPHPYii+11 | — | 1 partnership |
| 26 | Hyris Cloud-based software and genetic testing assay | $3M | 72 mo ago | 14 | Stefano Lo Priore CEO | JoomlaNode.jsPHP+12 | 16 patents Patents concentrated in computing, sensing & instrumentation | — |
| 27 | Mendelian Developer of an online platform that helps health care provider in diagnosing rare disease | $2M | 39 mo ago | 12 12 → 19 (+58%) | Francisco Tosina Co-Founder | UbuntuBootstrapNginx+14 | — | — |
| 28 | Synteny Provider of AI-based bioinformatic solutions for decoding genetic information | $2M | 37 mo ago | 3 | Lilly Wollman Co-Founder & CEO | WordPressMySQLPHP+6 | — | — |
| 29 | Resurgo Genetics Modeling cellular interactions to design precise interventions in living systems | $2M | 83 mo ago | — | Peter Clarke Founder | — | 3 patents Modulating gene transcription and expression using engineered genetic constructs | — |
| 30 | NGX Developer of personalised healthcare nutrition products based on genetic profiles | $2M | 39 mo ago | 5 | Jeremy Poland Co-Founder & CEO | Cart FunctionalityShopifySentry+46 | — | — |
| 31 | Omixy Complete -omics profile | $2M | 127 mo ago | 12 | — | — | — | — |
| 32 | OME Health Provider of personalized nutrition coaching programs and client management solutions | $1M | 48 mo ago | 2 | — | — | — | — |
| 33 | CC Bio Provider of synthetic biology platform for the development of drugs for microbiome-based diseases | $1M | 57 mo ago | 2 | Matthew Cummings Co-Founder & CEO | — | — | — |
| 34 | Rightangled Online pharmacy focused on personalized diagnostics and treatments | $647K | 73 mo ago | 12 12 → 28 (+133%) | — | Cart FunctionalityShopifySentry+35 | 5 patents Point‑of‑care immunoassay kits for detecting specific biomarkers in clinical samples | — |
| 35 | InSyBio Integrated platform providing tools for biological data management, secured storage and analysis | $600K | 93 mo ago | 1 | — | — | — | — |
| 36 | Mursla Provider of diagnostic device for cancer detection | $547K | 69 mo ago | 9 | Victor Serdio Co-Founder | NicepageWordPressMySQL+15 | 32 patents Isolation, characterization, and biosensor conditioning of tissue-specific extracellular vesicles. | 1 award |
| 37 | Odin Vision Provider of AI-based colon cancer detection platform | $368K | 85 mo ago | 12 | — | RubyAnimate.cssTailwind CSS+13 | — | — |
| 38 | Genomes Offers blockchain enabled security for sequenced genomes | $331K | 12 mo ago | 4 | Mark Hahnel Co-Founder | MediumTypeScriptGraphQL+17 | — | 1 launch |
| 39 | ClinGenics Provider of platform for genomic testing | $163K | 60 mo ago | 1 | Christopher Konialis Founder & Director | — | — | — |
| 40 | Nuntius Therapeutics Developer of DNA, RNA, and CRISPR therapies for rare diseases | $125K | 60 mo ago | 3 | Albert Kwok Co-Founder and CSO | — | 16 patents Peptide dendrimer nanocarriers for extrahepatic nucleic acid delivery and characterization | — |
| 41 | HelixNano Nanotechnology based solutions for DNA sequencing | $120K | 108 mo ago | 15 | Hannu Rajaniemi Co-Founder | — | — | — |
| 42 | Nell Health Provider of diet and health plan based on genetic tests | $120K | 108 mo ago | 16 | Laura Moore Founder & CEO | — | — | — |
Top 12 Genomics companies in London
#1
Series C · London, England · founded 2014$160.8Mraised▾
Provider of genomic risk assessment and prevention platform. This platform uses advanced polygenic risk scores and data science to predict individual risk of common diseases. It offers personalized tools and guidance for individuals, employers, and healthcare providers. The platform also assists life sciences companies in accelerating drug discovery and optimizing clinical trial design. The company's work contributes to more personalized and precise healthcare, ultimately aiming to improve health outcomes and reduce the cost of common diseases.
- Jan 2024Series C$44.5M
- Mar 2021Series B$30M
- Dec 2018Series B$10.1M
- Aug 2018Series B$32.3M
#2
Series A · London, England · founded 2013 · 4 employees$331.4Kraised▾
Genomes’ is a blockchain application designed to privately, securely store whole genome sequence data for an individual in a manner that allows questions to be asked of the genetic code without exposing the code to others. It uses Ethereum and Rockchain to allow systems to compute a function on private data, without exposing anything about their data besides the result.
- Jun 2025Series A—
- Jun 2024Series A—
- Jan 2020Seed$141.9K
- Jul 2018Seed$189.4K
#3
Series A · London, England · founded 2016 · 10 employees$26.5Mraised▾
Provider of clinical trial recruitment and genetic testing research services. The platform combines genetic testing, recruitment, and long-term engagement in one platform, accelerating enrollment and simplifying operations for precision medicine teams driving breakthroughs for patients.
- Jan 2024Series A$11.4M
- Aug 2023Grant (prize money)$419.3K
- Mar 2022Series A$11M
- Jan 2021Seed$3.4M
#4
Series A · London, England · founded 2008 · 18 employees$445.9Mraised▾
Provider of RNA activation therapeutics. It is focused on small activating RNA therapeutics that aim to restore or boost normal gene function. The company develops a proprietary pipeline of medicines and partners with pharmaceutical companies to apply its RNA activation technology across genetic medicine and other therapeutic areas.
- Jul 2021Series A$17.9M
- Sep 2020Series A$30M
- May 2019Series A$3.5M
- Nov 2017Series A$355.7M
#5
Seed · London, England · founded 2018 · 10 employees$9.1Mraised▾
Operator of cell therapy research and manufacturing platform designed to make bio-processing scalable and affordable for cell and gene therapy. The company's platform specializes in tackling the problems of process control and scalability with cell bioprocessing in particular for autologous cell and gene therapy, enabling biologists to carry out process development by running cell culture conditions in parallel with extreme process control and to scale up cells for manufacturing at a lower cost.
#6
Acqui-Hired · London, England · founded 2011 · 28 employees$121Mraised▾
Developer of antiviral compounds for RSV. The company is developing its lead candidate RV521 as an antiviral therapy for Respiratory Syncytial Virus (RSV), which is an infection that often leads to asthma, COPD, and/or pneumonia.
- Aug 2020Series C$44M
- Aug 2018Series B$55M
- Jul 2018Series B$55M
- Sep 2015Series A$21M
#7
Seed · London, England · founded 2017 · 6 employees$3.4Mraised▾
Provider of biomarker tests for precision treatments. The company offers biomarker tests to identify patients and demonstrate treatment efficacy for novel therapies. The company has laboratory manufacturing facilities certified by GLP and CLIA.
- Jan 2024Seed—
- Jan 2022Seed$2.5M
- Nov 2018Seed$984.8K
#8
Series A · London, England · founded 2019 · 38 employees$80Mraised▾
Developer of gene therapies for neurodegenerative disorders. The company is developing and delivering transformative gene therapies for diseases including frontotemporal dementia (FTD) and amyotrophic lateral sclerosis (ALS). The company's product candidate include AVB-PGRN an adeno-associated virus (AAV) gene therapy for patients with Frontotemporal Dementia (FTD) with mutations in the Progranulin (GRN) gene.
- Dec 2021Series A$80M
#9
Series B · London, England · founded 2015 · 14 employees$40.2Mraised▾
Femtogenix, a spin-out company from King’s College London (KCL) is a drug discovery company focussed on developing DNA-interactive payload molecules for use in antibody-drug conjugates (ADCs). Its drug discovery platform claims to enable the design molecules which are capable of binding reversibly and/or irreversibly to DNA, in a sequence-interactive manner, leading to exquisite cytotoxicity toward tumor cells and when attached to antibodies, these potent cytotoxic agents can be delivered directly to tumors. It is currently looking for a partnership with pharmaceutical companies.
- Mar 2022Series B$36.6M
- Sep 2015Series A$3.6M
#10
Series A · London, England · founded 2019 · 8 employees$9.3Mraised▾
Provider of lab-grown meat alternatives. The company claims it is using cells from livestock animals and multiplying them in the laboratory to obtain whole cuts of meat.
- Jan 2023Series A$7M
- Jan 2023Grant (prize money)$2.5M
- Jul 2021Seed$2.1M
- Jul 2021Grant (prize money)$146K
#11
Series A · London, England · founded 2015 · 32 employees$60Mraised▾
Provider of a lab-on‑chip wearable system for genetic diagnosis. It uses DNA + lifestyle data to guide personalized food and skincare choices in real time by using a cheek swab which is inserted into a disposable cartridge processed in a tabletop NudgeBox. It also offer Wearable DnaBand that syncs with smartphone app and allows barcode scanning of products and displays indicators based on genetic fit.
- Aug 2021Series A$60M
#12
Seed · London, England · founded 2018 · 6 employees$3.1Mraised▾
Provider of a platform predicting therapeutic response and outcome for cancer. The platform uses advanced modeling and predictions for science and clinical research. It translates disparate oncology datasets to uncover best indications with minimal data. The platform selects responders with patient-specific biomarkers and de-risks trials via in-silico simulations and digital controls.
- Sep 2023Seed$879.8K
- Mar 2023Seed$1.2M
- Nov 2021Seed$667.9K
- Mar 2021Seed$336.8K
Funding & investor landscape
Notable founders
Market landscape — 10 sub-themes by coverage
Share of Genomics coverage by sub-theme.
Regulatory-risk over time rising
Funding & growth over time
funding rising · growth rising
How research on Bioinformatics in London is moving
A read on the academic research around Bioinformatics in London — which themes are gaining ground, the institutions and researchers driving them, and how the tone is shifting. Based on 658 papers.
UCL, Imperial, and King's College London lead London's bioinformatics research, predominantly exploring genetic epidemiology and microbiome genomics with an optimistic tone toward clinical breakthroughs.
- University College London180
- Imperial College London179
- King\'s College London143
- Queen Mary University of London81
- London School of Hygiene & Tropical Medicine33
- Genome3→21
- Inference1→8
- Biomarker1→7
- Population1→7
- Metagenomics1→6
- Disease3→29
- Gene2→17
- DNA methylation1→7
- Epigenetics1→5
- Cancer4→7
- Disease3→28
- Immune system1→8
- Context (archaeology)2→7
- Metabolite1→3
- Drug1→3
Common questions
Riya reads income statements for fun. She covers the real money in a sector — revenue, growth, who actually earns — and never met a vague claim she didn't want a number for.